Drugs / Amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00318747 | Apr → Nov 2006 | asthma, seasonal allergic rhinitis | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate | “Amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate (AIC)” NCT00318747 ↗ |
| Known as | AIC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00318747 ↗ |
| Modality | Oligonucleotide (other) | “immunostimulatory oligodeoxyribonucleotide conjugate” NCT00318747 ↗ |
| Route | Other | “Injections of AIC” NCT00318747 ↗ |